Dublin, Nov. 12, 2015 (GLOBE NEWSWIRE) -- Research and Markets (http://www.researchandmarkets.com/research/6nl7q4/adc_contract) has announced the addition of the "ADC Contract Manufacturing Market (2nd edition), 2015-2025" report to their offering.

The report provides an extensive study of the contract manufacturing opportunity for the emerging class of ADCs. The report covers various aspects, such as identifying CMOs active in this space, their capabilities with respect to ADCs, available capacity (clinical / commercial) for bio-conjugation and geographic location / spread of the facilities.

With several drugs in the pipeline, the opportunity for contract manufacturers is likely to increase significantly in the coming years. One of the key objectives of this report is to understand the future potential for CMOs in the ADC market.

Amongst other things, the report elaborates on the following key areas:

- The current state of the market with respect to developmental stage of pipeline products (both clinical / pre-clinical) and indications targeted.
- Recent partnerships which have taken place over the last five years including product manufacturing agreements, technology collaborations and mergers / acquisitions.
- CMO investments to develop new / expand existing plants and supporting facilities in order to ensure sufficient production capacity and safe handling of these compounds.
- Upcoming growth areas and inherent threats to development in the short and long term.
- Development and sales potential of ADCs in advanced clinical stages; likely outsourcing profile across various steps involved in ADC manufacturing.

The base year for the report is 2015. The report provides short-mid term and long term market forecasts for the period 2015 - 2020 and 2020 - 2025, respectively. We have discussed, in detail, the key drivers behind the growth of the ADC contract manufacturing market. The research, analysis and insights presented in this report are backed by a comprehensive survey on ADC manufacturing capabilities of several CMOs.

In addition, we interviewed important stakeholders to solicit their opinions around the future opportunities and challenges which must be considered for a more inclusive growth. Examples of companies we interviewed include Piramal Healthcare, Pierre Fabre, Catalent, Lonza and BSP Pharmaceuticals.


- We expect Adcetris and Kadcyla,the two commercially available ADCs,to start generating annual sales of close to USD 1 billion in the near future. In addition to the marketed molecules, there are over 40 candidates in clinical development; of these, 25% are in Phase II & III.
- Seattle Genetics and Roche, with 7 and 6 molecules in clinical development respectively, currently have the most developed portfolio of ADC molecules. Relatively new entrants include (indicative list, in alphabetical order) AbGenomics, Abzena, Affinicon, Allozyne, Endo Pharmaceuticals, Formation Biologics, Intellect Neurosciences, Kairos Therapeutics, Menarini Biotech, Mersana Therapeutics, Oxford BioTherapeutics, Philochem, Synthon and Zymeworks; emergence of these firms is likely to provide the necessary push, both in terms of technology and innovation.
- Majority of ADC developers are dependent on contract manufacturers to supply the components. Discussions with senior experts in the industry reveal that around 70% of ADC manufacturing is currently outsourced.
- In less than two years, there has been a healthy increase in the number of CMOs providing services specific to ADC development; we have identified over 40 such CMOs. There are more than 20 CMOs with capabilities of manufacturing cytotoxics and providing conjugation services. Over 15 CMOs extend their fill/finish capabilities specific to ADC manufacturing.
- CMOs have been investing heavily to expand their manufacturing capabilities. In the last few years, there have been at least 15 published instances of investments from several CMOs to either expand their respective facilities or acquire new ones. Notably, CARBOGEN AMCIS has been one of the most active players.
- Collaborations have helped the market reach its current growth trajectory.For example, SAFC and Baxter BioPharma Solutions partnered to manufacture and conduct all the steps of ADC manufacturing to cater to the customer needs. Earlier, Goodwin and Coldstream had collaborated to act as full service providers of ADCs.
- In the base scenario, we anticipate the overall CMO market for ADC manufacturing to breach the USD 1 billion mark in the coming decade. In fact, there is a strong belief in the market that existing CMO facilities for ADC manufacturing will require expansion to cater to the growing population of pipeline molecules.

Key Topics Covered:

1. Preface

2. Executive Summary

3. Introduction

4. ADC Therapeutics: Development Overview

5. Manufacturing of ADCs: A Market Overview

6. CMOs: Worldwide Landscape

7. Profiles of Leading Companies

8. Recent Developments

9. Market Size and Forecast

10. SWOT Analysis

11. Conclusion

12. Interview Transcripts

13. Appendix 1: Tabulated Data

14. Appendix 2: List of Companies and Organisations

- AAIPharma Services Corp
- AbbVie
- AbGenomics
- ACES Pharma
- ADC Biotechnology
- ADC Therapeutics
- Affinicon
- Affinity Lifesciences
- Allozyne
- ALMAC Group
- Ambrx
- Amgen
- AMRI Global
- Aspyrian Therapeutics
- Astellas Pharma/Agensys
- Asymchem
- Baxter BioPharma Solutions
- Bayer Healthcare
- Ben Venue Laboratories
- BioAgilytix Labs
- BioOutsource
- Biotechnique
- Biotest AG
- Boehringer Ingelheim
- Bristol Myers Squibb
- BSP Pharmaceuticals
- Cambrex Corporation
- Catalent
- Celldex Therapeutics
- Cerbios-Pharma SA
- ChemCon
- ChemPartner
- Chugai Pharmaceuticals
- CMC Biologics
- Coldstream Laboratories
- Concortis
- Creative Biolabs
- CuraGen
- CytomX Therapeutics
- Cytovance Biologics LLC
- Daiichi Sankyo
- Dalton Pharma Services
- Dishman Group
- DSM Pharmaceuticals
- EirGenix
- Eli Lilly
- Endo Pharmaceuticals
- Esperance Pharmaceuticals
- Eucodis Bioscience
- Evonik
- Ferro Pfanstiehl
- Formation Biologics
- Formosa Laboratories
- FUJIFILM Diosynth Biotechnologies
- Gallus Biopharmaceuticals
- Genmab
- Goodwin Biotechnology
- Heidelberg Pharma
- Heraeus Precious Metals
- IDT Australia
- ImmunoGen
- Immunomedics
- Innate Pharma
- Intellect Neurosciences
- Kairos Therapeutics
- Kemwell
- Lonza
- Menarini Biotech
- Merck
- Mersana Therapeutics
- Millennium
- MiMabs
- National Cancer Institute
- National Research Council Canada
- NBE Therapeutics
- Novartis
- Novasep
- Oxford BioTherapeutics
- Pacific GMP
- Patheon
- Pfizer/Wyeth
- Philochem
- Pierre Fabre
- Piramal Pharma Solutions
- Progenics Pharmaceuticals
- Project Pharmaceutics
- QPS Holdings
- Quanta BioDesign
- Redwood Bioscience
- Roche/Genentech
- SafeBridge Consultants
- Sandoz
- Sanofi
- Sanofi Aventis
- Seattle Genetics
- Società Italiana Corticosteroidi S.r.l (SICOR)
- Spirogen
- Stem CentRx
- Symbiosis Pharmaceutical Services
- Synthon
- Takeda Pharmaceuticals
- The Chemistry Research Solution
- Waters
- Wuxi PharmaTech
- Wyeth Europa Ltd.
- Zhejiang Medicine Co. Ltd.
- Zymeworks

For more information visit http://www.researchandmarkets.com/research/6nl7q4/adc_contract

CONTACT: Research and Markets
Laura Wood, Senior Manager

For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Sector: Pharmaceuticals